A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.
about
Biomarkers and biometric measures of adherence to use of ARV-based vaginal ringsHIV, sexual violence and special populations: adolescence and pregnancyResearch gaps in defining the biological link between HIV risk and hormonal contraceptionMTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartmentsQuantitative analysis of microbicide concentrations in fluids, gels and tissues using confocal Raman spectroscopyThe importance of the vaginal delivery route for antiretrovirals in HIV prevention.HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediatorsEvaluation of 3 approaches for assessing adherence to vaginal gel application in clinical trials.Use of the dye stain assay and ultraviolet light test for assessing vaginal insertion of placebo-filled applicators before and after sexAltered biomarkers of mucosal immunity and reduced vaginal Lactobacillus concentrations in sexually active female adolescents.A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive.Lactobacillus proteins are associated with the bactericidal activity against E. coli of female genital tract secretionsTopical prophylaxis for HIV prevention in women: becoming a reality.Innate immunity in the vagina (Part II): Anti-HIV activity and antiviral content of human vaginal secretionsNuclear receptor signaling inhibits HIV-1 replication in macrophages through multiple trans-repression mechanismsValidation of a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators.A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infectionBacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity.RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarateDose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir GelAssociation of High-Risk Human Papillomavirus with Genital Tract Mucosal Immune Factors in HIV-Infected Women.Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.Longitudinal Assessment of Systemic and Genital Tract Inflammatory Markers and Endogenous Genital Tract E. coli Inhibitory Activity in HIV-Infected and Uninfected Women.Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse ModelChanges in the soluble mucosal immune environment during genital herpes outbreaks.Comparison of Follicular and Luteal Phase Mucosal Markers of HIV Susceptibility in Healthy WomenPlasma and mucosal HIV viral loads are associated with genital tract inflammation in HIV-infected women.Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention.Antiretroviral bioanalysis methods of tissues and body biofluids.Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1.Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?Methodological lessons from clinical trials and the future of microbicide research.Secreted mucosal antimicrobials in the female reproductive tract that are important to consider for HIV prevention.Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease.
P2860
Q26753097-6A895DE7-915C-4985-B2E2-F90890BD968EQ26825943-E7F0F438-79F2-4EE2-BEA0-179977DC2A7BQ27002559-AB884413-98D8-405C-AE3E-B85206C612D0Q28485356-056B9FED-1C11-4077-A9C3-4E950BC3D885Q28538105-5B780F66-09FA-459D-B7D1-49391F749F6CQ30414890-2EB765D8-4635-47F2-8E60-976641571274Q33763000-08414FA0-AEF4-462A-9130-4ABD43C792F0Q33821090-731549A6-38A2-4ECB-A730-8E7A266D7BE0Q33999185-98563011-3B7E-448E-9EDF-3FC71F70ADC1Q34034381-9EA69A73-723A-4E1C-B0CD-DD759EB82C36Q34084215-2A017DBF-39EC-406C-A6A3-F9A0DC7CB165Q34342009-2602A553-5E05-4DB8-9E91-453C169A4DF9Q34414539-520DC423-7402-4654-B9AB-C3EA0174023FQ34442460-9852866B-4D91-4AED-903C-8D06F4C6C334Q34490101-19414C96-EDCA-415E-99FE-4DC0A0F46444Q35031133-C41C68C5-392D-4DB6-9925-D07C48B2F9BFQ35078336-AE849630-8945-421B-B62D-7E190F41B2D1Q35274791-EBB2256C-1A13-4A2E-ADCF-D1A14A2B206FQ35534646-F58E0D2B-0CEE-4933-AC1A-270AD26D0091Q36286901-075E753B-482F-4792-B851-9EDFBD606C90Q36294698-61EF8971-E34E-451C-9A74-FC65B2BB5F1BQ36359092-F72B3125-783A-4555-ADC1-125343571E14Q36406923-6FB860FE-6F98-4F7B-9678-CB0E5739F483Q36446138-C684EA79-85D4-4882-8A9C-220C959F7302Q36471518-7AA40883-B9CE-483F-898B-A06043F6C3E5Q36644606-00E469BF-07CA-4EC2-AE34-DE3432780574Q36927695-3E6CFC7D-9E6F-45F4-AE40-BCBE675F7AC5Q36933427-DA348590-67DB-469B-A8E2-3E789D7CA695Q36937188-90631DA5-C241-4C64-9265-4865D8415F5BQ36966645-A4165158-64F7-4F10-8283-756479926B36Q36996000-D69CBD9A-4503-4667-AB68-C789CA91442DQ37042094-77FFCBC6-8AF7-41AF-8C9F-D21C84551D5BQ37203867-3C3C9DE4-F9F7-415E-8F0C-C519B5387CCEQ37258271-60FCFD0E-83B1-4D32-829A-83F9F7D6F043Q37332868-EDF4CDE7-7E33-4014-9E2B-6A2E40354EDAQ37694939-7517DD4F-52EB-403D-AA93-94778A4AFF2CQ38009758-CBFC4225-31F1-4366-A790-380CA2752252Q38062882-D9CCD4DF-0A2F-4B0F-ABD6-241B9BC959F1Q38206217-CE206962-F323-4091-8EC1-2D3E301122CAQ38248209-97018808-AC28-4773-8D06-BBE5509AD6CA
P2860
A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A randomized trial to assess a ...... plication of 1% tenofovir gel.
@ast
A randomized trial to assess a ...... plication of 1% tenofovir gel.
@en
type
label
A randomized trial to assess a ...... plication of 1% tenofovir gel.
@ast
A randomized trial to assess a ...... plication of 1% tenofovir gel.
@en
prefLabel
A randomized trial to assess a ...... plication of 1% tenofovir gel.
@ast
A randomized trial to assess a ...... plication of 1% tenofovir gel.
@en
P2093
P2860
P1433
P1476
A randomized trial to assess a ...... plication of 1% tenofovir gel.
@en
P2093
Anna C Lee
Betsy C Herold
Craig W Hendrix
Erin C Diament
Gail Shust
Jianmeng Chen
Lydia Soto-Torres
Marla J Keller
Melissa J Fazzari
N Merna Torres
P2860
P304
P356
10.1371/JOURNAL.PONE.0016475
P407
P577
2011-01-25T00:00:00Z